RedHill Biopharma (RDHL) Assets (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Assets for 3 consecutive years, with $18.0 million as the latest value for Q4 2024.

  • Quarterly Assets fell 21.71% to $18.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $18.0 million through Dec 2024, down 21.71% year-over-year, with the annual reading at $18.0 million for FY2024, 21.71% down from the prior year.
  • Assets for Q4 2024 was $18.0 million at RedHill Biopharma, down from $23.0 million in the prior quarter.
  • The five-year high for Assets was $158.9 million in Q4 2022, with the low at $18.0 million in Q4 2024.
  • Average Assets over 3 years is $66.7 million, with a median of $23.0 million recorded in 2023.
  • The sharpest move saw Assets tumbled 85.49% in 2023, then dropped 21.71% in 2024.
  • Over 3 years, Assets stood at $158.9 million in 2022, then crashed by 85.49% to $23.0 million in 2023, then decreased by 21.71% to $18.0 million in 2024.
  • According to Business Quant data, Assets over the past three periods came in at $18.0 million, $23.0 million, and $158.9 million for Q4 2024, Q4 2023, and Q4 2022 respectively.